CTMX FY 2023 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$101M+90.4% YoY

Gross Profit

$101M100.0% margin

Operating Income

-$6M-6.4% margin

Net Income

-$569,000-0.6% margin

EPS (Diluted)

$-0.01

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$57M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$202M

Total Liabilities

$249M

Stockholders' Equity

-$47M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$53M	+90.4%
Gross Profit	$101M	$53M	+90.4%
Operating Income	-$6M	-$101M	+93.6%
Net Income	-$569,000	-$99M	+99.4%